Short Interest in OmniAb, Inc. (NASDAQ:OABIW) Increases By 98.0%

OmniAb, Inc. (NASDAQ:OABIW) was the recipient of a large growth in short interest in the month of August. As of August 14th, there was short interest totaling 18,488 shares, a growth of 98.0% from the July 30th total of 9,338 shares. Based on an average daily trading volume, of 6,868 shares, the short-interest ratio is presently 2.7 days.

OmniAb Stock Up 4.0%

Shares of OABIW opened at $0.26 on Tuesday. OmniAb has a 12 month low of $0.04 and a 12 month high of $0.40. The firm’s 50 day moving average is $0.12 and its 200-day moving average is $0.10.

OmniAb Company Profile

OmniAb, Inc is a clinical‐stage biotechnology company specializing in the discovery and optimization of therapeutic antibodies. The company leverages a broad suite of proprietary platform technologies designed to accelerate antibody generation, characterization, and engineering. By integrating advanced immunization methods with high‐throughput screening and bioinformatics, OmniAb aims to streamline the development of next‐generation biologics across a range of disease areas.

At the core of OmniAb’s offering are its transgenic animal platforms, which have been engineered to produce fully human antibodies, and its complementary in vitro display and single‐cell screening capabilities.